Interview: Qiu Jiazhou – MD Chairman, H-Guard, China
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Founded in August 2013 by four returnees scientists and entrepreneurs, H-Guard is a high-tech enterprise integrating the R&D, production and sales of medical devices.
Having introduced a number of international leading biomedical projects and in vitro diagnostic projects from the United States, our flagship product is the latest in vitro diagnostic kit for early warning of myocardial infarction and cerebral infarction risk. We are also developing other POCT cardiovascular disease diagnostic reagents and have core material production technology.
| Address | #604, Building 1, Shenzhen Biomedicine Innovations Industry Park, 14 Jinhui Road, Pingshan District, Shenzhen, PRC |
| Tel | +86 755 8945 9910 |
| Website | http://www.h-guard.com.cn/ |
| ivd@h-guard.com.cn |
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
From factory automation in Silicon Valley to scalable service robotics embedded in daily care, Roy Long Hei’s journey with Robocore reflects a disciplined belief that technology must prove itself in…
Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed,…
Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In…
See our Cookie Privacy Policy Here
